Panobinostat Maintenance After HSCT fo High-risk AML and MDS

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2020
Aim of this prospective randomized trial is to compare maintenance treatment with panobinostat interspersed with donor lymphocyte infusions (DLI) versus the standard approach of pre-emptive DLI alone in patients with poor-risk AML/MDS having favorably received an allogeneic HSCT followed by engraftment, donor chimerism and hematopoietic reconstitution.
Epistemonikos ID: 8e5e87a725fe14738efa22136c4f5cf2bb97ef55
First added on: Jan 21, 2022